FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891765403> ?p ?o ?g. }

• W2891765403 endingPage "e21068" @default.
• W2891765403 startingPage "e21068" @default.
• W2891765403 abstract "e21068 Background: A large randomized non-inferiority trial (COMPARZ) demonstrated comparable efficacy but better tolerability and health-related quality of life (HRQOL) with PZ vs SU in treatment-naïve pts with mRCC. Preference-based measures of HRQOL (utilities) were not assessed in the trial, however. The objective of this study was to estimate utilities for pts receiving PZ and SU using data on adverse events (AEs) observed in COMPARZ. Methods: Two analyses were conducted. First, a regression model relating AEs to utilities was estimated using data from the VEG105192 trial, a phase 3 randomized controlled trial of PZ vs. placebo in mRCC pts. The dependent variable in this regression was the EQ-5D utility index value. Independent variables were age, sex, performance status, prior treatment, treatment group, and AEs experienced on the day of each assessment. AEs were characterized by (1) grade and (2) whether the AE was observed more frequently in SU vs. PZ pts in COMPARZ. Using the estimated regression model, utilities were estimated for each day of pre-progression follow-up for all pts in COMPARZ based on baseline characteristics and AEs present on each day. Mean utilities during PFS were then calculated for each treatment group using Kaplan-Meier methods. Confidence intervals were obtained by bootstrapping. In a secondary analysis, mean utilities for PZ and SU in COMPARZ were calculated by combining AE data from COMPARZ with estimated utilities for AEs from published studies. Results: With utilities based on the regression model derived from VEG105192, mean (95%CI) utilities during PFS were 0.709 (0.67, 0.75) for PZ and 0.683 (0.64, 0.73) for SU (difference = 0.026 (0.004, 0.050)). With utilities based on published estimates, mean (95%CI) utilities during PFS were 0.739 (0.73, 0.75) for PZ and 0.708 (0.70, 0.72) for SU (difference = 0.030 (0.016, 0.044)). Conclusions: Differences in the AE profiles of PZ and SU may yield differences in mean utility values. These findings, which are consistent with results of analyses of HRQOL in COMPARZ and patient preferences in the PISCES trial, may have important implications for the relative cost-effectiveness of PZ and SU. Clinical trial information: NCT00720941." @default.
• W2891765403 created "2018-09-27" @default.
• W2891765403 creator A5001188908 @default.
• W2891765403 creator A5038694515 @default.
• W2891765403 creator A5039896263 @default.
• W2891765403 date "2016-05-20" @default.
• W2891765403 modified "2023-10-13" @default.
• W2891765403 title "Utility values among patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line treatment with pazopanib (PZ) and sunitinib (SU)." @default.
• W2891765403 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.e21068" @default.
• W2891765403 hasPublicationYear "2016" @default.
• W2891765403 type Work @default.
• W2891765403 sameAs 2891765403 @default.
• W2891765403 citedByCount "3" @default.
• W2891765403 countsByYear W28917654032017 @default.
• W2891765403 countsByYear W28917654032020 @default.
• W2891765403 countsByYear W28917654032023 @default.
• W2891765403 crossrefType "journal-article" @default.
• W2891765403 hasAuthorship W2891765403A5001188908 @default.
• W2891765403 hasAuthorship W2891765403A5038694515 @default.
• W2891765403 hasAuthorship W2891765403A5039896263 @default.
• W2891765403 hasConcept C126322002 @default.
• W2891765403 hasConcept C126894567 @default.
• W2891765403 hasConcept C142724271 @default.
• W2891765403 hasConcept C143998085 @default.
• W2891765403 hasConcept C168563851 @default.
• W2891765403 hasConcept C197934379 @default.
• W2891765403 hasConcept C204787440 @default.
• W2891765403 hasConcept C27081682 @default.
• W2891765403 hasConcept C2777472916 @default.
• W2891765403 hasConcept C2778375690 @default.
• W2891765403 hasConcept C2778439243 @default.
• W2891765403 hasConcept C2779490328 @default.
• W2891765403 hasConcept C44249647 @default.
• W2891765403 hasConcept C50382708 @default.
• W2891765403 hasConcept C71924100 @default.
• W2891765403 hasConceptScore W2891765403C126322002 @default.
• W2891765403 hasConceptScore W2891765403C126894567 @default.
• W2891765403 hasConceptScore W2891765403C142724271 @default.
• W2891765403 hasConceptScore W2891765403C143998085 @default.
• W2891765403 hasConceptScore W2891765403C168563851 @default.
• W2891765403 hasConceptScore W2891765403C197934379 @default.
• W2891765403 hasConceptScore W2891765403C204787440 @default.
• W2891765403 hasConceptScore W2891765403C27081682 @default.
• W2891765403 hasConceptScore W2891765403C2777472916 @default.
• W2891765403 hasConceptScore W2891765403C2778375690 @default.
• W2891765403 hasConceptScore W2891765403C2778439243 @default.
• W2891765403 hasConceptScore W2891765403C2779490328 @default.
• W2891765403 hasConceptScore W2891765403C44249647 @default.
• W2891765403 hasConceptScore W2891765403C50382708 @default.
• W2891765403 hasConceptScore W2891765403C71924100 @default.
• W2891765403 hasIssue "15_suppl" @default.
• W2891765403 hasLocation W28917654031 @default.
• W2891765403 hasOpenAccess W2891765403 @default.
• W2891765403 hasPrimaryLocation W28917654031 @default.
• W2891765403 hasRelatedWork W1014013009 @default.
• W2891765403 hasRelatedWork W2166445840 @default.
• W2891765403 hasRelatedWork W2254527377 @default.
• W2891765403 hasRelatedWork W2345625238 @default.
• W2891765403 hasRelatedWork W2893778816 @default.
• W2891765403 hasRelatedWork W3202900078 @default.
• W2891765403 hasRelatedWork W4214919057 @default.
• W2891765403 hasRelatedWork W4282046442 @default.
• W2891765403 hasRelatedWork W4286959671 @default.
• W2891765403 hasRelatedWork W4380896460 @default.
• W2891765403 hasVolume "34" @default.
• W2891765403 isParatext "false" @default.
• W2891765403 isRetracted "false" @default.
• W2891765403 magId "2891765403" @default.
• W2891765403 workType "article" @default.